Warm Autoimmune Hemolytic Anemia Waiha Market Size

DelveInsight's 'Warm Autoimmune Hemolytic Anemia (wAIHA ) - Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of WAIHA  in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Warm Autoimmune Hemolytic Anemia (wAIHA) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.


Geography Covered

• The United States

• EU5 (Germany, France, Italy, Spain and the United Kingdom)

• Japan


Study Period: 2017-2028


Warm Autoimmune Hemolytic Anemia (wAIHA) - Disease Understanding and Treatment Algorithm

The DelveInsight Warm Autoimmune Hemolytic Anemia (wAIHA) market report gives the thorough understanding of the Warm Autoimmune Hemolytic Anemia by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Warm Autoimmune Hemolytic Anemia in the US, Europe, and Japan.


Warm Autoimmune Hemolytic Anemia Epidemiology

The Warm Autoimmune Hemolytic Anemia (wAIHA) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases of AIHA, total prevalent cases of wAIHA, type-specific prevalent cases, prevalent cases based on gender) scenario of Warm Autoimmune Hemolytic Anemia (wAIHA ) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

According to DelveInsight, the total number of prevalent cases of Warm Autoimmune Hemolytic Anemia (wAIHA) in 7 MM was found to be 82,807, in the year 2017.


Warm Autoimmune Hemolytic Anemia Drug Chapters

This segment of the Warm Autoimmune Hemolytic Anemia report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The market forecast solely focuses on the market revenue generated by the pharmacological treatment (inclusive of corticosteroids as the first line of therapy, second line of therapy includes : splenectomy, Rituximab, immunosuppressive drugs such as Cyclosporin A whereas Alemtuzumab and hematopoietic stem cell transplantation (HSCT) are considered as the options of last resort.. Detailed chapter for upcoming therapies like Fostamatinib (Rigel Pharmaceuticals) and APL-2 (Apellis Pharmaceuticals, Inc.) have been covered in the report.


Warm Autoimmune Hemolytic Anemia Market Outlook

The Warm Autoimmune Hemolytic Anemia market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Warm Autoimmune Hemolytic Anemia in 7MM was found to be USD 280.0 million in 2017, and is expected to increase at a CAGR of XX% from 2017-2028.


Warm Autoimmune Hemolytic Anemia Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.


Warm Autoimmune Hemolytic Anemia Report Insights

• Patient Population

• Therapeutic Approaches

• Pipeline Analysis

• Market Size and Trends

• Market Opportunities

• Impact of upcoming Therapies


Warm Autoimmune Hemolytic Anemia Report Key Strengths

• 10 Year Forecast

• 7MM Coverage

• Epidemiology Segmentation

• Drugs Uptake

• Highly Analyzed Market

• Key Cross Competition


Warm Autoimmune Hemolytic Anemia Report Assessment

• Current Treatment Practices

• Unmet Needs

• Detailed Pipeline Product Profiles

• Market Attractiveness

• Market Drivers and Barriers


Key Benefits

• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Warm Autoimmune Hemolytic Anemia market

• Organize sales and marketing efforts by identifying the best opportunities for Warm Autoimmune Hemolytic Anemia market

• To understand the future market competition in the Warm Autoimmune Hemolytic Anemia market.


What is Warm Autoimmune Hemolytic Anemia (WAIHA)?

Warm Autoimmune Hemolytic Anemia (WAIHA) is a dysfunction in the immune system resulting in immune system attacking its red blood cells considering them foreign substances at a temperature of 37 °C (98.6 °F).


At what CAGR, Warm Autoimmune Hemolytic Anemia (WAIHA) market is expected to grow for the study period 2017-30?

The current Warm AIHA market is positively evolving and will continue to grow at a CAGR of 15.9% in the 7MM by 2030.


What was the Warm Autoimmune Hemolytic Anemia (WAIHA) market size in the US?

The Warm AIHA market size in the US was estimated to be USD 163.4 Million approximately in 2017.


Which are the leading companies in Warm Autoimmune Hemolytic Anemia (WAIHA) market?

Key companies such as Rigel Pharmaceuticals, Apellis Pharmaceuticals, Inc., Momenta Pharmaceuticals, Alexion Pharmaceuticals, Immunovant and others are anticipated to impact the WAIHA market positively.


Which therapy is expected to grab the maximum share in Warm Autoimmune Hemolytic Anemia (WAIHA) market during the study period 2017-30?

DelveInsight analysts estimate that fostamatinib – a candidate of Rigel – will significantly occupy the Warm autoimmune hemolytic anemia market share for the forecast period (2019-2028)


How is epidemiology segmented for Warm Autoimmune Hemolytic Anemia (WAIHA)?

Warm Autoimmune Hemolytic Anemia Epidemiology is segmented into Total and diagnosed prevalence, gender-specific prevalence, and sub-type specific prevalence.

1. Key Insights

2. wAIHA Market Overview at a Glance

2.1. Market Share (%) Distribution of wAIHA in 2017

2.2. Market Share (%) Distribution of wAIHA in 2028

3. Disease Background and Overview

3.1. Introduction

3.2. Types

3.3. Signs and Symptoms

3.4. Pathophysiology

3.5. Diagnosis

3.6. Immunohematological assessment of patients with AIHA

4. Epidemiology and Patient Population

4.1. Key Findings

4.2. Population and Forecast Parameters

4.3. KOL Views

4.4. 7MM Total Prevalent Patient Population of wAIHA

5. Country Wise-Epidemiology of wAIHA

5.1. The United States

5.1.1. Assumptions and Rationale

5.1.2. Total Prevalent Cases of AIHA in the United States

5.1.3. Prevalence of wAIHA in the United States

5.1.4. Type-specific Prevalence of wAIHA in the United States

5.1.5. Gender-specific Prevalence of wAIHA in the United States

5.2. EU5

5.2.1. Assumptions and Rationale

5.3. Germany

5.3.1. Total Prevalent Cases of AIHA in Germany

5.3.2. Prevalence of wAIHA in Germany

5.3.3. Type-specific Prevalence of wAIHA in Germany

5.3.4. Gender-specific Prevalence of wAIHA in Germany

5.4. France

5.4.1. Total Prevalent Cases of AIHA in France

5.4.2. Prevalence of wAIHA in France

5.4.3. Type-specific Prevalence of wAIHA in France

5.4.4. Gender-specific Prevalence of wAIHA in France

5.5. Italy

5.5.1. Total Prevalent Cases of AIHA in Italy

5.5.2. Prevalence of wAIHA in Italy

5.5.3. Type-specific Prevalence of wAIHA in Italy

5.5.4. Gender-specific Prevalence of wAIHA in Italy

5.6. Spain

5.6.1. Total Prevalent Cases of AIHA in Spain

5.6.2. Prevalence of wAIHA in Spain

5.6.3. Type-specific Prevalence of wAIHA in Spain

5.6.4. Gender-specific Prevalence of wAIHA in Spain

5.7. The United Kingdom

5.7.1. Total Prevalent Cases of AIHA in the UK

5.7.2. Prevalence of wAIHA in the UK

5.7.3. Type-specific Prevalence of wAIHA in the UK

5.7.4. Gender-specific Prevalence of wAIHA in the UK

5.8. Japan

5.8.1. Assumptions and Rationale

5.8.2. Total Prevalent Cases of AIHA in Japan

5.8.3. Prevalence of wAIHA in Japan

5.8.4. Type-specific Prevalence of wAIHA in Japan

5.8.5. Gender-specific Prevalence of wAIHA in Japan

6. Treatment and Management of WAIHA

6.1. Sequential approach to treatment options for w-AIHA and common dosing regimens

6.1.1. First-line therapy

6.1.2. Second-line therapy

7. Unmet Needs

8. Emerging Therapies

8.1. Fostamatinib: Rigel Pharmaceuticals

8.1.1. Product Description

8.1.2. Other Development Activities

8.1.3. Clinical Development

8.1.4. Safety and Efficacy

8.1.5. Product Profile

8.2. APL-2: Apellis Pharmaceuticals, Inc.

8.2.1. Product Description

8.2.2. Other Development Activities

8.2.3. Clinical Development

8.2.4. Safety and Efficacy

8.2.5. Product Profile

8.3. Other Promising Candidates

8.3.1. SYNT001: Alexion Pharmaceuticals, Inc.

8.3.2. BIV009 (Sutimlimab): Sanofi

9. wAIHA: 7 Major Market Analysis

9.1. Key Findings

9.2. Market Size of wAIHA in 7MM

9.3. KOL Views

10. Market Outlook by Country

10.1. The United States: Market Outlook

10.2. United States Market Size

10.2.1. Total Market Size of wAIHA

10.2.2. Market Size of wAIHA by Line of Therapies (LoT)

10.2.3. Market Size of wAIHA by Emerging Therapies

11. EU-5 Countries: Market Outlook

11.1. Germany

11.1.1. Total Market size of wAIHA

11.1.2. Market Size of wAIHA by Line of Therapies (LoT)

11.1.3. Market Size of wAIHA by Emerging Therapies

11.2. France

11.2.1. Total Market Size of wAIHA

11.2.2. Market Size of wAIHA by Line of Therapies (LoT)

11.2.3. Market Size of wAIHA by Emerging Therapies

11.3. Italy

11.3.1. Total Market Size of wAIHA

11.3.2. Market Size of wAIHA by Line of Therapies (LoT)

11.3.3. Market Size of wAIHA by Emerging Therapies

11.4. Spain

11.4.1. Total Market Size of wAIHA

11.4.2. Market Size of wAIHA by Line of Therapies (LoT)

11.4.3. Market Size of wAIHA by Emerging Therapies

11.5. United Kingdom

11.5.1. Total Market Size of wAIHA

11.5.2. Market Size of wAIHA by Line of Therapies (LoT)

11.5.3. Market Size of wAIHA by Emerging Therapies

12. Japan: Market Outlook

12.1. Total Market Size of wAIHA

12.2. Market Size of wAIHA by Line of Therapies (LoT)

12.3. Market Size of wAIHA by Emerging Therapies

13. Market Drivers

14. Market Barriers

15. Appendix

15.1. Report Methodology

16. DelveInsight Capabilities

17. Disclaimer

18. About DelveInsight

Table 1: Classification of wAIHA

Table 2: Prevalent Patient Population of wAIHA in 7MM (2017-2028)

Table 3: Total Prevalent Cases of AIHA in the United States (2017-2028)

Table 4: Prevalence of wAIHA in the United States (2017-2028)

Table 5: Type-specific Prevalence of wAIHA in the United States (2017-2028)

Table 6: Gender-specific Prevalence of wAIHA in the United States (2017-2028)

Table 7: Total Prevalent Cases of AIHA in Germany (2017-2028)

Table 8: Prevalence of wAIHA in Germany (2017-2028)

Table 9: Type-specific Prevalence of wAIHA in Germany (2017-2028)

Table 10: Gender-specific Prevalence of wAIHA in Germany (2017-2028)

Table 11: Total Prevalent Cases of AIHA in France (2017-2028)

Table 12: Prevalence of wAIHA in France (2017-2028)

Table 13: Type-specific Prevalence of wAIHA in France (2017-2028)

Table 14: Gender-specific Prevalence of wAIHA in France (2017-2028)

Table 15: Total Prevalent Cases of AIHA in Italy (2017-2028)

Table 16: Prevalence of wAIHA in Italy (2017-2028)

Table 17: Type-specific Prevalence of wAIHA in Italy (2017-2028)

Table 18: Gender-specific Prevalence of wAIHA in Italy (2017-2028)

Table 19: Total Prevalent Cases of AIHA in Spain (2017-2028)

Table 20: Prevalence of wAIHA in Spain (2017-2028)

Table 21: Type-specific Prevalence of wAIHA in Spain (2017-2028)

Table 22: Gender-specific Prevalence of wAIHA in Spain (2017-2028)

Table 23: Total Prevalent Cases of AIHA in the UK (2017-2028)

Table 24: Prevalence of wAIHA in the UK (2017-2028)

Table 25: Type-specific Prevalence of wAIHA in the UK (2017-2028)

Table 26: Gender-specific Prevalence of wAIHA in the UK (2017-2028)

Table 27: Total Prevalent Cases of AIHA in Japan (2017-2028)

Table 28: Prevalence of wAIHA in Japan (2017-2028)

Table 29: Type-specific Prevalence of wAIHA in Japan (2017-2028)

Table 30: Gender-specific Prevalence of wAIHA in Japan (2017-2028)

Table 31: Treatment Flow

Table 32: Fostamatinib, Clinical Trial Description, 2019

Table 33: APL-2, Clinical Trial Description, 2019

Table 34: SYNT001, Clinical Trial Description, 2019

Table 35: BIV009, Clinical Trial Description, 2019

Table 36: 7 Major Market Size of wAIHA in USD Million (2017-2028)

Table 37: United States Market Size of wAIHA in USD Million (2017-2028)

Table 38: The US Market Size of wAIHA by LoT in USD Million (2017-2028)

Table 39: The US Market Size of wAIHA by Emerging Therapies in USD Million (2017-2028)

Table 40: Germany Market Size of wAIHA in USD Million (2017-2028)

Table 41: Germany Market Size of wAIHA by LoT in USD Million (2017-2028)

Table 42: Germany Market Size of wAIHA by Emerging Therapies in USD Million (2017-2028)

Table 43: France Market Size of wAIHA in USD Million (2017-2028)

Table 44: France Market Size of wAIHA by LoT in USD Million (2017-2028)

Table 45: France Market Size of wAIHA by Emerging Therapies in USD Million (2017-2028)

Table 46: Italy Market Size of wAIHA in USD Million (2017-2028)

Table 47: Italy Market Size of wAIHA by LoT in USD Million (2017-2028)

Table 48: Italy Market Size of wAIHA by Emerging Therapies in USD Million (2017-2028)

Table 49: Spain Market Size of wAIHA in USD Million (2017-2028)

Table 50: Spain Market Size of wAIHA by LoT in USD Million (2017-2028)

Table 51: Spain Market Size of wAIHA by Emerging Therapies in USD Million (2017-2028)

Table 52: The United Kingdom Market Size of wAIHA in USD Million (2017-2028)

Table 53: The UK Market Size of wAIHA by LoT in USD Million (2017-2028)

Table 54: The UK Market Size of wAIHA by Emerging Therapies in USD Million (2017-2028)

Table 55: Japan Market Size of wAIHA in USD Million (2017-2028)

Table 56: Japan Market Size of wAIHA by LoT in USD Million (2017-2028)

Table 57: Japan Market Size of wAIHA by Emerging Therapies in USD Million (2017-2028)

Figure 1: Mechanisms of antibody-sensitized RBC destruction in w-AIHA

Figure 2: Prevalent Patient Population of wAIHA in 7MM (2017-2028)

Figure 3: Total Prevalent Cases of AIHA in the United States (2017-2028)

Figure 4: Prevalence of wAIHA in the United States (2017-2028)

Figure 5: Type-specific Prevalence of wAIHA in the United States (2017-2028)

Figure 6: Gender-specific Prevalence of wAIHA in the United States (2017-2028)

Figure 7: Total Prevalent Cases of AIHA in Germany (2017-2028)

Figure 8: Prevalence of wAIHA in Germany (2017-2028)

Figure 9: Type-specific Prevalence of wAIHA in Germany (2017-2028)

Figure 10: Gender-specific Prevalence of wAIHA in Germany (2017-2028)

Figure 11: Total Prevalent Cases of AIHA in France (2017-2028)

Figure 12: Prevalence of wAIHA in France (2017-2028)

Figure 13: Type-specific Prevalence of wAIHA in France (2017-2028)

Figure 14: Gender-specific Prevalence of wAIHA in France (2017-2028)

Figure 15: Total Prevalent Cases of AIHA in Italy (2017-2028)

Figure 16: Prevalence of wAIHA in Italy (2017-2028)

Figure 17: Type-specific Prevalence of wAIHA in Italy (2017-2028)

Figure 18: Gender-specific Prevalence of wAIHA in Italy (2017-2028)

Figure 19: Total Prevalent Cases of AIHA in Spain (2017-2028)

Figure 20: Prevalence of wAIHA in Spain (2017-2028)

Figure 21: Type-specific Prevalence of wAIHA in Spain (2017-2028)

Figure 22: Gender-specific Prevalence of wAIHA in Spain (2017-2028)

Figure 23: Total Prevalent Cases of AIHA in the UK (2017-2028)

Figure 24: Prevalence of wAIHA in the UK (2017-2028)

Figure 25: Type-specific Prevalence of wAIHA in the UK (2017-2028)

Figure 26: Gender-specific Prevalence of wAIHA in the UK (2017-2028)

Figure 27: Total Prevalent Cases of AIHA in Japan (2017-2028)

Figure 28: Prevalence of wAIHA in Japan (2017-2028)

Figure 29: Type-specific Prevalence of wAIHA in Japan (2017-2028)

Figure 30: Gender-specific Prevalence of wAIHA in Japan (2017-2028)

Figure 31: Treatment algorithm for warm AIHA in adults

Figure 32: Unmet Needs of wAIHA

Figure 33: 7 Major Market Size of wAIHA in USD Million (2017-2028)

Figure 34: Market Size of wAIHA in the United States, USD Million (2017-2028)

Figure 35: The US Market Size of wAIHA by LoT in USD Million (2017-2028)

Figure 36: The US Market Size of wAIHA by Emerging Therapies in USD Million (2017-2028)

Figure 37: Market Size of wAIHA in Germany, USD Million (2017-2028)

Figure 38: Germany Market Size of wAIHA by LoT in USD Million (2017-2028)

Figure 39: The US Market Size of wAIHA by Emerging Therapies in USD Million (2017-2028)

Figure 40: Market Size of wAIHA in France USD Million (2017-2028)

Figure 41: France Market Size of wAIHA by LoT in USD Million (2017-2028)

Figure 42: The US Market Size of wAIHA by Emerging Therapies in USD Million (2017-2028)

Figure 43: Market Size of wAIHA in Italy, USD Million (2017-2028)

Figure 44: Italy Market Size of wAIHA by LoT in USD Million (2017-2028)

Figure 45: Italy Market Size of wAIHA by Emerging Therapies in USD Million (2017-2028)

Figure 46: Market Size of wAIHA in Spain, USD Million (2017-2028)

Figure 47: Spain Market Size of wAIHA by LoT in USD Million (2017-2028)

Figure 48: Spain Market Size of wAIHA by Emerging Therapies in USD Million (2017-2028)

Figure 49: Market Size of wAIHA in the United Kingdom, USD Million (2017-2028)

Figure 50: The UK Market Size of wAIHA by LoT in USD Million (2017-2028)

Figure 51: The UK Market Size of wAIHA by Emerging Therapies in USD Million (2017-2028)

Figure 52: Market Size of wAIHA in Japan, USD Million (2017-2028)

Figure 53: Japan Market Size of wAIHA by Therapies in USD Million (2017-2028)

Figure 54: Japan Market Size of wAIHA by Emerging Therapies in USD Million (2017-2028)

Figure 55: Market Drivers

Figure 56: Market Barriers

  • Tags:
  • Warm Autoimmune Hemolytic Anemia (w...
  • Warm Autoimmune Hemolytic Anemia (w...
  • Warm Autoimmune Hemolytic Anemia (w...
  • Warm Autoimmune Hemolytic Anemia (w...
  • Warm Autoimmune Hemolytic Anemia (w...
  • Warm Autoimmune Hemolytic Anemia (w...
  • Warm Autoimmune Hemolytic Anemia (w...
  • Warm Autoimmune Hemolytic Anemia (w...
  • Warm Autoimmune Hemolytic Anemia (w...
  • Warm Autoimmune Hemolytic Anemia (w...
  • Warm Autoimmune Hemolytic Anemia (w...
  • Warm Autoimmune Hemolytic Anemia (w...
  • Warm Autoimmune Hemolytic Anemia (w...
  • Warm Autoimmune Hemolytic Anemia (w...
  • Warm Autoimmune Hemolytic Anemia (w...
  • Warm Autoimmune Hemolytic Anemia (...

Forward to Friend

Need A Quote